回盛生物(300871.SZ)：上半年公司投入研发费用3153.24万元

Core Viewpoint - The company is increasing its investment in research and technological innovation, focusing on the development of new veterinary drugs to enhance product competitiveness [1] Group 1: R&D Investment - In the first half of 2025, the company invested CNY 31.53 million in R&D, representing a 19.16% increase compared to the same period last year [1] Group 2: Product Development and Approvals - The company is accelerating the efficiency of new drug approvals and production transitions, continuously advancing the approval of new veterinary drugs and comparative products [1] - As of June 30, 2025, the company has obtained 19 new veterinary drug registration certificates, including 4 new certificates in the first half of 2025 for products such as Mianping Ointment, Enconazole, Enconazole Solution, and Qijqing Extract Powder [1] - The company has obtained a total of 219 veterinary drug approval numbers [1]